Caribou Biosciences, Inc. - CRBU STOCK NEWS

Caribou Biosciences reported promising advancements in its Q3 2021 financial results, with cash and equivalents of $435.3 million, bolstered by a successful IPO that raised $321.0 million. The company is progressing with its lead candidate, CB-010, in the ANTLER Phase 1 trial for non-Hodgkin lymphoma, aiming to share initial data in 2022. Caribou's proprietary chRDNA technology provides enhanced specificity for genome edits, crucial for developing CAR-T therapies. The firm also welcomed new board members and a chief business officer, enhancing its leadership team.

Caribou Biosciences (Nasdaq: CRBU) announced the appointment of Dara Richardson-Heron to its board and Ruhi Khan as chief business officer. Dr. Richardson-Heron brings over 25 years of healthcare experience, while Ms. Khan contributes 20 years of business development expertise. Both appointments are aimed at advancing Caribou’s allogeneic cell therapies, including the Phase 1 candidate CB-010. The company leverages its chRDNA genome-editing technology to develop CAR-T and CAR-NK therapies targeting hematologic malignancies and solid tumors.

Caribou Biosciences, a leading CRISPR genome-editing biopharmaceutical company, announced that its CEO, Rachel Haurwitz, will present at two upcoming investor conferences. The presentations are scheduled for the Jefferies Gene Therapy/Editing Summit on October 27 and the Barclays Gene Editing & Gene Therapy Summit on November 15. Live webcasts will be available on Caribou's website, with archived versions accessible for 30 days post-event. Caribou is focused on developing next-generation therapies using its proprietary chRDNA technology to enhance genome editing precision.

Caribou Biosciences (Nasdaq: CRBU) has appointed Ran Zheng to its board of directors, effective immediately. Zheng brings over 25 years of experience in the biotechnology industry, particularly in biologics drug development and gene therapy manufacturing. Her addition aims to enhance the company's capabilities as it advances its chRDNA-edited allogeneic CAR-T and CAR-NK cell therapies targeting hematologic malignancies and solid tumors. Zheng's prior roles include leadership positions at Landmark Bio and Orchard Therapeutics, contributing to significant advancements in gene therapy products.

Caribou Biosciences (CRBU), a CRISPR genome-editing biopharmaceutical company, announced that CEO Rachel Haurwitz will participate in a fireside chat on October 4, 2021, at the Chardan Virtual 5th Annual Genetic Medicines Conference. Haurwitz will also be part of a panel discussion titled "Gene Editing: Next-Generation Technologies Worth Watching" on October 5, 2021. The live webcast will be available on Caribou's website, with an archived version accessible for 30 days post-event.

Caribou aims to advance genome-edited therapies using its proprietary chRDNA technology.

Caribou Biosciences (Nasdaq:CRBU) has published data in Molecular Cell outlining its proprietary CRISPR hybrid RNA-DNA (chRDNA) technology, demonstrating enhanced genome editing specificity.

The study reveals that chRDNA guides outperform all-RNA guides in reducing off-target edits while achieving efficient genomic modifications, crucial for the development of CAR-T therapies targeting hematologic malignancies.

Initial clinical data from ongoing trials of their multiplex-edited candidate CB-010 is anticipated in 2022, signaling significant potential for therapeutic advancements.

Caribou Biosciences, Inc. (Nasdaq: CRBU) completed an upsized IPO, raising $349.6 million, alongside reporting Q2 2021 financial results. The company dosed its first patient in the ANTLER Phase 1 trial for CB-010 targeting relapsed B cell non-Hodgkin lymphoma. However, Caribou faced a substantial decrease in licensing revenue, down to $1.5 million from $8.5 million year-over-year. R&D expenses rose to $12.3 million, while G&A expenses increased to $5.1 million, contributing to a net loss of $14.3 million, a notable rise from the previous year's $1.9 million loss.

Caribou Biosciences, Inc. (Nasdaq: CRBU) announced that CEO Rachel Haurwitz, Ph.D., will join a panel at Citi’s 16th Annual BioPharma Virtual Conference on September 9, 2021, at 10:40 am ET. The panel, titled “Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy,” will focus on advances in cell therapies. A live and archived webcast will be available for 30 days on the company’s website. Caribou is committed to developing next-generation, genome-edited cell therapies using its proprietary technology.

Caribou Biosciences (Nasdaq: CRBU) has appointed Nancy Whiting, Pharm.D., to its board of directors. With over 17 years in biotechnology, Whiting has extensive experience in drug development, especially in oncology, which aligns with Caribou’s focus on advancing its cell therapy pipeline. Her previous role was as executive vice president at Seagen Inc., where she led late-stage clinical development. The company aims to leverage her expertise as it develops CRISPR-edited therapies for cancer treatment.